The study, led by investigators at Shanxi Medical University, tackled a long-standing puzzle in cardiac aging research. Scientists have known that mitochondria, the power plants of the cell, deteriorate as hearts grow old. But the precise mechanism linking that deterioration to the broader decline of the aging myocardium has remained elusive. Because natural aging in mice takes many months and carries high mortality, the team used doxorubicin, a chemotherapy drug well established to produce cardiac damage that closely mimics natural cardiac aging, including mitochondrial dysfunction, enlargement of individual cardiomyocytes, and weakened contraction. They treated young male C57BL/6J mice with repeated low doses of the drug, building up a cumulative regimen that reliably induced senescence in heart tissue.

The first major finding concerned a process called mitophagy, the specialized form of autophagy that clears out damaged mitochondria. Under normal conditions, worn-out mitochondria are tagged, engulfed by autophagosomes, and delivered to lysosomes for degradation, keeping the mitochondrial network healthy. In the aging hearts, electron microscopy revealed a striking accumulation of mitophagosomes—structures that had captured damaged mitochondria but were never processed further. Levels of the autophagy marker LC3B-II and the cargo receptor p62 were simultaneously elevated, a classic signature of a blocked degradative pathway. When the researchers applied chloroquine, a drug that halts lysosomal degradation, to young cells, mitochondrial–LC3B colocalization rose sharply; in aged cells, the drug produced no further increase, indicating that the degradative arm of mitophagy was already saturated. In other words, the aging heart was not failing to initiate mitophagy—it was failing to finish it, creating a traffic jam of half-processed cellular garbage.

The consequences of this congestion were visible throughout the senescent cardiomyocytes. Live-cell imaging showed mitochondria that were shorter, rounder, and more fragmented than those in healthy cells, with fewer branch points and reduced network integrity. Flow cytometry using the MitoSOX probe revealed a significant surge in mitochondrial superoxide, a reactive oxygen species generated by dysfunctional mitochondria. Energy production faltered, oxidative stress mounted, and the senescence program advanced: senescence-associated beta-galactosidase activity climbed, and the proteins p16 and apolipoprotein E—well-established markers of cellular aging—rose in both the mouse hearts and in HL-1 cardiomyocytes treated with doxorubicin in culture.

Enter the therapy. The team isolated mitochondria from murine bone marrow mesenchymal stem cells, a source chosen for its regenerative potential and shared mesodermal origin with cardiomyocytes, and delivered them through the tail vein at 0.5 milligrams per kilogram every two days for six injections. Fluorescent tracing with MitoTracker-labeled mitochondria, monitored by whole-body imaging over 24 hours, confirmed that the organelles reached the cardiac region, and time-lapse microscopy captured them entering cardiomyocytes in culture. The results were dramatic. Echocardiography showed significant recovery of left ventricular fractional shortening and ejection fraction, along with reduced end-systolic volume. Wheat germ agglutinin staining revealed smaller, less hypertrophied cardiomyocytes, senescence staining dropped markedly, and electron microscopy showed fewer mitophagosomes, more intact mitochondria, and restored cristae density. Superoxide levels fell, and the senescence markers p16 and APOE declined in both tissue and cultured cells.

To find the molecular switch behind this rejuvenation, the researchers turned to multi-omics. RNA sequencing of aged versus young hearts identified 27 differentially expressed mitochondrial genes, and one stood out: Bnip3, which encodes an atypical BCL-2 family protein embedded in the mitochondrial outer membrane. BNIP3 normally acts as a mitophagy receptor, recruiting the autophagosome marker LC3B through its LC3-interacting region to initiate mitochondrial clearance. In the aging heart, BNIP3 was dramatically overexpressed, and its expression correlated far more strongly with the autophagy marker Map1lc3b than did PINK1, the canonical ubiquitin-dependent mitophagy pathway, whose Parkin protein levels were unchanged. Crucially, the pattern was conserved across species: hearts from 80-week-old naturally aged mice showed elevated BNIP3, and single-cell RNA sequencing of human heart datasets from GSE156703 and the Heart Cell Atlas revealed significantly higher BNIP3 expression in aged human cardiomyocytes.

Functional experiments confirmed that BNIP3 was not merely a bystander but a driver of senescence. When the researchers forced BNIP3 overexpression in HL-1 cardiomyocytes, the cells developed the full senescent phenotype—elevated p16 and APOE, increased beta-galactosidase staining, and rising levels of LC3B-II and p62 that signaled autophagic congestion. Conversely, when BNIP3 was overexpressed in cells that had received mitochondrial transplantation, the therapy’s benefits vanished: senescence staining returned to aged levels, LC3B–mitochondria colocalization climbed back up, and the accumulated autophagy proteins reappeared. This reversal experiment demonstrated that downregulation of BNIP3 is essential for mitochondrial transplantation to work.

The upstream regulator proved to be an unexpected player. Screening transcription factors altered in the aging heart, the team identified HIF-3α, the least-studied member of the hypoxia-inducible factor family, long regarded mainly as a transcriptional repressor. Here it acted as an activator. Bioinformatic prediction with JASPAR revealed a high-affinity HIF-3α binding site in the Bnip3 promoter, dual-luciferase reporter assays confirmed that HIF-3α could drive Bnip3 transcription, and chromatin immunoprecipitation followed by quantitative PCR pinned down the binding at a specific promoter site. Overexpressing HIF-3α raised BNIP3 levels; silencing it with siRNA lowered them. HIF-1α, the family’s famous member, showed no significant changes, indicating a distinct, non-redundant pathway. HIF-3α was also elevated in aged mouse hearts and aged human cardiomyocytes, and clinical data from heart failure samples in prior literature align with the axis’s upregulation.

Perhaps the most provocative discovery concerns what HIF-3α actually senses: energy. When the researchers measured ATP, they found that mitochondrial transplantation markedly boosted energy levels in aged cardiac tissue. To test whether ATP fluctuations drive the axis, they treated cardiomyocytes with CCCP, a chemical that collapses mitochondrial membrane potential and depletes ATP. ATP levels fell, and HIF-3α rose in response. The emerging model is elegant: as the aging heart’s mitochondria falter and ATP production drops, the energy crisis stabilizes HIF-3α, which switches on BNIP3, floods the cell with mitophagy receptors, and jams the mitophagy flux. Transplanting fresh mitochondria restores ATP, HIF-3α and BNIP3 subside, and the disposal system flows freely again.

The findings arrive as mitochondrial transplantation itself moves into early clinical exploration. Phase I trials in pediatric ischemia-reperfusion injury have already demonstrated preserved cardiomyocyte viability, and systematic reviews support the approach’s potential to restore myocardial bioenergetics, with encouraging safety data showing no immune responses after autologous transplantation. Significant questions remain before aging hearts could be treated this way: the precise mechanism by which HIF-3α senses low ATP is still unknown, whether transplanted mitochondria physically fuse with the recipient’s mitochondrial network has not been directly visualized, and no clinical safety evaluations exist for this application. Delivery routes also pose challenges, from the invasiveness of intramyocardial injection to the low cardiac targeting efficiency of intravenous administration. Still, by identifying the HIF-3α–BNIP3 axis as a druggable control point for mitophagy flux, the study offers something the field has lacked—a concrete molecular explanation for why aging hearts clog their own cleanup machinery, and a demonstration that the clog can be cleared.

Subject of Research: Mitochondrial transplantation therapy for cardiac aging via restoration of mitophagy flux through the HIF-3α–BNIP3 pathway

Article Title: Mitochondrial Transplantation Rejuvenates Aging Heart by Restoring Mitophagy Flux via the HIF‐3α‐BNIP3 Axis

Article References: Mitochondrial Transplantation Rejuvenates Aging Heart by Restoring Mitophagy Flux via the HIF‐3α‐BNIP3 Axis. (n.d.). https://doi.org/10.1111/acel.70720

Image Credits: AI Generated

DOI: 10.1111/acel.70720

Keywords: mitochondrial transplantation, cardiac aging, mitophagy, BNIP3, HIF-3α, senescence, mesenchymal stem cells, doxorubicin, ATP, autophagy flux, cardiomyocytes, Aging Cell